$BIEI - Premier Biomedical, Inc. (OTCQB: $BIEI)
Revealed the results of its latest cancer immunotherapy work being conducted by its research partner, UTEP, at the recent American Association for Cancer Research (AACR) Conference, in New Orleans. The patent-pending anti-cancer antibody is intended to compete in the immunotherapy segment of the $100 plus billion cancer treatment market, with drugs like Yervoy® by Bristol Meyers Squibb who is projecting sales of $14 billion by 2018.
William A. Hartman, President and CEO of Premier Biomedical, stated, “This new drug has shown to be effective in blocking 98.8% of CTLA-4 breast cancer-causing antigens in laboratory tests, compared to 36% for the drug we presented in 2014. In our mouse testing, both of these antibodies demonstrated immunity to re-injections of breast cancer after treatment.”
Hartman indicated that the company plans comparison tests of other available immunotherapy drugs to verify the belief that this new antibody may be the most effective anti-breast cancer drug in the world. “We have also developed antibodies against other cancer-causing antigens and plan animal tests to compare them to other available treatments in the near future,” he said.
https://upticknewswire.com/premier-biomedical...rma-drugs/
Revealed the results of its latest cancer immunotherapy work being conducted by its research partner, UTEP, at the recent American Association for Cancer Research (AACR) Conference, in New Orleans. The patent-pending anti-cancer antibody is intended to compete in the immunotherapy segment of the $100 plus billion cancer treatment market, with drugs like Yervoy® by Bristol Meyers Squibb who is projecting sales of $14 billion by 2018.
William A. Hartman, President and CEO of Premier Biomedical, stated, “This new drug has shown to be effective in blocking 98.8% of CTLA-4 breast cancer-causing antigens in laboratory tests, compared to 36% for the drug we presented in 2014. In our mouse testing, both of these antibodies demonstrated immunity to re-injections of breast cancer after treatment.”
Hartman indicated that the company plans comparison tests of other available immunotherapy drugs to verify the belief that this new antibody may be the most effective anti-breast cancer drug in the world. “We have also developed antibodies against other cancer-causing antigens and plan animal tests to compare them to other available treatments in the near future,” he said.
https://upticknewswire.com/premier-biomedical...rma-drugs/
The information provided above came to you from Uptick Newswire (herein referred to as “us”, “we” or “the website”) is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. All information that we provide is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Furthermore, investing in such securities involves substantial risk of loss and investors should seek advice from financial professionals before investing.
Uptick Newswire provides social media outreach and Investor Relations services for Micro-Cap companies. These are paid services. We may from time to time hold shares of companies featured as payment for services rendered. It is understood that Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that the investor’s entire investment may be lost or impaired due to the speculative nature of the companies listed.
Uptick Newswire makes no recommendation that the securities of the companies listed should be purchased, sold or held by individuals or entities that learn of the listed companies through Uptick Newswire representatives or upticknewswire.com. Any suggestions made by Uptick Newswire staff regarding companies featured on upticknewswire.com is solely that “a suggestion” nothing more. It is our expectation that investors will do their own due diligence.
We recommend that readers use the information found within as a starting point for conducting their own research on the featured company in order to determine their own personal opinion of the company before investing. Uptick Newswire is not liable for any investment decisions made by our readers. Readers should investigate and fully understand all risks before investing.
Uptick Newswire provides social media outreach and Investor Relations services for Micro-Cap companies. These are paid services. We may from time to time hold shares of companies featured as payment for services rendered. It is understood that Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that the investor’s entire investment may be lost or impaired due to the speculative nature of the companies listed.
Uptick Newswire makes no recommendation that the securities of the companies listed should be purchased, sold or held by individuals or entities that learn of the listed companies through Uptick Newswire representatives or upticknewswire.com. Any suggestions made by Uptick Newswire staff regarding companies featured on upticknewswire.com is solely that “a suggestion” nothing more. It is our expectation that investors will do their own due diligence.
We recommend that readers use the information found within as a starting point for conducting their own research on the featured company in order to determine their own personal opinion of the company before investing. Uptick Newswire is not liable for any investment decisions made by our readers. Readers should investigate and fully understand all risks before investing.
